Krishna Institute of Medical Sciences Ltd
Krishna Institute of Medical Sciences Ltd
Healthcare ServicesKey Fundamentals
SmallcapHospitalsHealthcare ServicesInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Krishna Institute of Medical Sciences Ltd insights
42 extracted metrics + investor summaries across FY05–FY27.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company is expected to give good quarter
- Company's median sales growth is 21.9% of last 10 years
Weaknesses
4- Stock is trading at 14.2 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -1.62%
- Company might be capitalizing the interest cost
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 5d agoKrishna Institute of Medical Sciences Ltd (KIMS) is a rapidly expanding hospital chain with FY26 consolidated revenue of ₹3,931 crore (up 28.6% YoY) but faces near-term profit pressure — Q4 FY26 net profit fell 58% YoY to ₹42.5 crore as EBITDA margins contracted to ~19.2% from ~24.8% due to new hospital ramp-up costs. The stock trades at a P/E of 173.7x and 14.3x book value, reflecting high growth expectations against a backdrop of elevated net debt (~₹3,100 crore as of March 2026).
- FY26 consolidated revenue grew 28.6% YoY to ₹3,931 crore, demonstrating consistent top-line momentum
- 10-year compounded sales CAGR of 23% and median sales growth of 21.9% over the last decade indicate a durable growth franchise
- Bed capacity expanded to ~6,464 beds across 25 hospitals in five states, up from ~3,975 in FY24, providing a long runway for revenue growth as occupancy ramps
- Q1 FY27 revenue surged 36.1% YoY to ₹1,196 crore, indicating acceleration even beyond FY26 levels
- Management projects 20-25% annual revenue and EBITDA growth through FY28, supported by new units in Bangalore and Thane ramping toward 30%+ occupancy
- FY25 EBITDA grew 24.7% YoY to ₹8,148 million, showing margin scalability in mature hospitals before new-unit drag
- Company plans to reduce debt by ~₹1,000 crore using promoter funding and QIP proceeds, which should lower interest burden and improve PAT trajectory
- Stock has delivered a 3-year price CAGR of 29%, reflecting market recognition of the structural healthcare demand story in South India
- Trailing P/E of 173.7x is extremely elevated, pricing in years of flawless execution with little margin of safety
- Q4 FY26 net profit collapsed 58% YoY to ₹42.5 crore despite 34% revenue growth, as EBITDA margin fell to 19.2% from 24.8%
- Net debt stood at approximately ₹3,100 crore as of March 2026, driven by aggressive capex on seven new hospitals launched in 2025
- TTM compounded profit declined 43%, and the 3-year profit CAGR is negative at -9%, showing earnings have not kept pace with revenue
- Occupancy across the network is only 50.5% in FY26 (operational beds 4,825 of 6,464), meaning new hospitals are generating losses that dilute group margins
- Stock trades at 14.3x book value with zero dividend yield — the company retains all profits yet ROE has fallen to 11% in the last year from a 5-year average of 18%
- Promoter holding decreased by 1.62% in the latest quarter, signaling potential dilution or reduced skin-in-the-game
- Company may be capitalizing interest costs, which flatters reported profits and understates true operating expenses during the expansion phase
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 20h ago- PAT drops 57% on expansion costs Aug 8
Q1FY27 PAT fell 56.5% YoY to ₹37 crore despite strong revenue, driven by higher depreciation and interest costs from aggressive expansion.
- Elevated leverage strategy at 2.5x Aug 4
KIMS targets a debt-to-equity ratio of ~2.5:1, prioritizing greenfield expansion over debt repayment, signaling sustained leverage pressure.
- FY26 net profit down 42% Aug 5
Full-year FY26 PAT declined 41.7% to ₹2,420 million despite 28.2% revenue growth to ₹39,308 million, as expansion costs weighed heavily.
- QIP fund commingling flagged Aug 3
CARE Ratings flagged commingling of QIP proceeds with general corporate funds after KIMS utilized ₹1,084 crore of ₹1,500 crore QIP in Q1FY27.
- Q1FY27 revenue surges 36% YoY Aug 8
Consolidated revenue jumped 36.1% YoY to ₹1,196 crore in Q1FY27, with EBITDA rising 20.1% to ₹240 crore on operational expansion.
- Promoter warrants approved at ₹779 Aug 7
BSE and NSE granted in-principle approval to issue 77,02,182 warrants to promoters at ₹779 each, signaling promoter confidence.
- Q2 expected to outperform Q1 Aug 4
Management guided for Q2 outperformance driven by new hospitals gaining operational momentum and progressive scale-up of recently added facilities.
- Q1FY26 revenue up 35%, profit grows Aug 3
Q1FY26 consolidated revenue rose 35% YoY to ₹11,795 million with net profit growing 7% QoQ, supported by QIP-funded expansion.
- AGM set for Aug 27 Aug 5
24th AGM scheduled for August 27, 2026 with shareholders to vote on ₹650 crore loan/guarantee limits and cost auditor fee ratification.
- BRSR report filed for FY26 Aug 5
KIMS submitted its Business Responsibility and Sustainability Report for FY26 with reasonable assurance by M/s. Brahmayya & Co.
- Analyst meet at Emkay Confluence Aug 4
KIMS to participate in Emkay Confluence 2026 group meeting on August 12, 2026 in Mumbai; no UPSI to be shared.
- Q1FY27 earnings call published Aug 4
Audio recording of Q1FY27 investor conference call published on company website, compliant with SEBI LODR regulations.
TL;DR: KIMS is delivering strong top-line growth (35-36% YoY revenue increases) driven by aggressive hospital expansion, but profitability is under significant pressure with PAT declining 42-57% due to elevated depreciation and interest costs. Promoter warrant issuance and management's Q2 outperformance guidance signal confidence, but the deliberate 2.5x leverage target and CARE Ratings' commingling flag are near-term risks. The trend favors revenue momentum with margin recovery contingent on new hospitals maturing over the next 2-3 quarters.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 606 | 652 | 606 | 634 | 688 | 777 | 772 | 797 | 872 | 961 | 998 | 1,075 | 1,180 |
| Expenses | 449 | 475 | 459 | 475 | 509 | 559 | 585 | 599 | 679 | 757 | 799 | 868 | 956 |
| Operating Profit | 157 | 177 | 147 | 159 | 179 | 218 | 187 | 198 | 193 | 204 | 199 | 206 | 223 |
| OPM % | 26% | 27% | 24% | 25% | 26% | 28% | 24% | 25% | 22% | 21% | 20% | 19% | 19% |
| Other Income | 3 | 3 | 3 | 4 | 5 | 5 | 18 | 15 | 7 | 4 | 5 | 1 | 17 |
| Interest | 9 | 9 | 12 | 16 | 18 | 20 | 26 | 27 | 33 | 45 | 57 | 68 | 83 |
| Depreciation | 32 | 33 | 35 | 46 | 39 | 41 | 45 | 53 | 53 | 66 | 79 | 85 | 101 |
| PBT | 119 | 139 | 102 | 100 | 127 | 162 | 135 | 134 | 114 | 97 | 69 | 55 | 57 |
| Tax % | 27% | 27% | 25% | 28% | 25% | 26% | 31% | 21% | 25% | 26% | 24% | 40% | 34% |
| Net Profit | 87 | 101 | 77 | 72 | 95 | 121 | 92 | 106 | 85 | 72 | 52 | 33 | 37 |
| EPS in Rs | 2.02 | 2.3 | 1.8 | 1.64 | 2.16 | 2.68 | 2.22 | 2.54 | 1.96 | 1.67 | 1.33 | 1.06 | 0.99 |
Profit & Loss
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 512 | 567 | 664 | 918 | 1,123 | 1,330 | 1,651 | 2,198 | 2,498 | 3,035 | 3,905 | 4,212 |
| Expenses | 403 | 450 | 593 | 833 | 872 | 953 | 1,126 | 1,587 | 1,850 | 2,242 | 3,090 | 3,380 |
| Operating Profit | 109 | 118 | 71 | 85 | 251 | 377 | 524 | 611 | 648 | 793 | 815 | 833 |
| OPM % | 21% | 21% | 11% | 9% | 22% | 28% | 32% | 28% | 26% | 26% | 21% | 20% |
| Other Income | 5 | 3 | 37 | 6 | 5 | 9 | 27 | 41 | 13 | 43 | 17 | 28 |
| Interest | 37 | 32 | 88 | 49 | 44 | 37 | 22 | 37 | 55 | 100 | 215 | 253 |
| Depreciation | 36 | 35 | 40 | 56 | 71 | 70 | 73 | 129 | 147 | 177 | 283 | 331 |
| PBT | 41 | 53 | -20 | -15 | 141 | 279 | 457 | 485 | 460 | 558 | 334 | 277 |
| Tax % | 32% | 37% | 126% | 223% | 18% | 26% | 25% | 25% | 27% | 26% | 28% | — |
| Net Profit | 28 | 33 | -46 | -49 | 115 | 205 | 344 | 366 | 336 | 415 | 242 | 194 |
| EPS in Rs | 0.76 | 0.91 | -1.32 | -1.28 | 3.2 | 5.19 | 8.32 | 8.41 | 7.75 | 9.61 | 6.03 | 5.05 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 70 | 72 | 50 | 74 | 74 | 78 | 80 | 80 | 80 | 80 | 80 |
| Reserves | 193 | 255 | -209 | 466 | 524 | 786 | 1,307 | 1,590 | 1,748 | 2,058 | 2,167 |
| Borrowings | 256 | 280 | 753 | 336 | 369 | 316 | 257 | 678 | 1,355 | 2,562 | 4,253 |
| Other Liabilities | 146 | 167 | 359 | 237 | 228 | 253 | 260 | 553 | 636 | 990 | 1,190 |
| Total Liabilities | 665 | 774 | 954 | 1,114 | 1,194 | 1,433 | 1,904 | 2,901 | 3,820 | 5,689 | 7,691 |
| Fixed Assets | 515 | 518 | 755 | 863 | 916 | 931 | 1,005 | 1,766 | 2,434 | 3,348 | 5,710 |
| CWIP | 2 | 64 | 0 | 0 | 2 | 9 | 21 | 477 | 600 | 1,214 | 606 |
| Investments | 11 | 14 | 0 | 0 | 0 | 0 | 332 | 68 | 157 | 99 | 103 |
| Other Assets | 137 | 177 | 199 | 250 | 276 | 493 | 546 | 590 | 629 | 1,028 | 1,271 |
| Total Assets | 665 | 774 | 954 | 1,114 | 1,194 | 1,433 | 1,904 | 2,901 | 3,820 | 5,689 | 7,691 |
Cash Flow
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 95 | 82 | 106 | 134 | 202 | 356 | 324 | 432 | 521 | 582 | 511 |
| Investing | -41 | -100 | -64 | -110 | -125 | -354 | -412 | -416 | -753 | -1,116 | -1,452 |
| Financing | -65 | 24 | -39 | -27 | -44 | 10 | 61 | 20 | 217 | 543 | 940 |
| Net Cash Flow | -11 | 5 | 3 | -3 | 32 | 12 | -26 | 36 | -15 | 9 | -1 |
| Free Cash Flow | 61 | -18 | 49 | 57 | 150 | 262 | 154 | -140 | -125 | -380 | -902 |
| CFO/OP | 88 | 80 | 192 | 195 | 102 | 104 | 86 | 87 | 102 | 91 | 81 |
Ratios
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47 | 59 | 59 | 49 | 43 | 30 | 28 | 42 | 43 | 48 | 52 |
| Inventory Days | 36 | 43 | 46 | 47 | 44 | 30 | 37 | — | — | — | — |
| Days Payable | 194 | 207 | 215 | 181 | 177 | 167 | 133 | — | — | — | — |
| Cash Conversion Cycle | -111 | -105 | -110 | -85 | -91 | -106 | -67 | 42 | 43 | 48 | 52 |
| Working Capital Days | 11 | 26 | -333 | -15 | -15 | -31 | -3 | 8 | -5 | -29 | -37 |
| ROCE % | — | 15% | 11% | 5% | 20% | 29% | 34% | 24% | 17% | 15% | 10% |
Documents
Frequently Asked Questions about Krishna Institute of Medical Sciences Ltd
What does Krishna Institute of Medical Sciences Ltd do?
Where is Krishna Institute of Medical Sciences Ltd (KIMS) listed?
Which sector does Krishna Institute of Medical Sciences Ltd belong to?
What is the market capitalisation of Krishna Institute of Medical Sciences Ltd?
What is the PE ratio of Krishna Institute of Medical Sciences Ltd?
What is the 52-week high and low of Krishna Institute of Medical Sciences Ltd?
What is the Return on Equity (ROE) of Krishna Institute of Medical Sciences Ltd?
How can I research Krishna Institute of Medical Sciences Ltd on Tapetide?
Company Information
Krishna Medical Institution Ltd (KIMS) was Incorporated in the year 1973 and is one of the largest corporate healthcare groups in Andhra Pradesh and Telangana in terms of patients treated and treatments offered. The company offers multidisciplinary healthcare services with primary, secondary, and tertiary care across 2-3 tier cities and an additional quaternary healthcare facility in tier-1 cities.